Compassionate Use of 3, 4-Diaminopyridine in Lambert Eaton Myasthenic Syndrome
Aims: Treatment of Lambert-Eaton Myasthenic Syndrome
Principal Investigator:
David Randall, DO
NorthShore Project Number:  EH02-041
Funding source:  NorthShore University HealthSystem
Contact:
  Please call 847.657.5875 with questions regarding the study
Open to enrollment: Yes

An Open-Label, Expanded Access Protocol for Firdapse® (Amifampridine Phosphate; 3,4-Diaminopyridine Phosphate) Treatment in Patients with Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS) and Downbeat Nystagmus
Aims: The primary objective of the study is to provide patients with LEMS/CMS/downbeat nystagmus access to amifampridine phosphate therapy until the product becomes commercially available. The secondary objective of the study is to assess the long-term safety of amifampridine.
Principal Investigator: Alexandru Barboi, MD
NorthShore Project Number: EH16-121
Contact: Please call 847.570.4046 with questions regarding the study
Open to enrollment: Yes

Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS)
Aims: Some neuropathies are secondary to readily identifiable causes. For approximately 25 to 50% of neuropathies, through, the cause is unknown. These are referred to as cryptogenic sensory polyneuropathy (CSPN). The primary aims of this study are: 1) to determine which of four pharmaceutical therapies is most effective in producing pain relief and improving quality of life in patients with CSPN, and 2) to determine which drug causes the fewest side effects, and which drug causes the most side effects. The four drugs being evaluated are nortriptyline, duloxetine, pregabalin and mexiletine.
Principal Investigator: Alexandru Barboi, MD
NorthShore Project Number: EH17-011
Contact: Call 847.503.4322 with questions regarding the study.
Open to enrollment: Yes